Prostate cancer therapy using immune checkpoint molecules to target recombinant dendritic cells
Investigative and Clinical Urology · 2024
DOI: 10.4111/icu.20230348 ↗Kurz gefasst
Fachartikel in der Zeitschrift Investigative and Clinical Urology, 2024. Verfasst von Se Young Choi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Chung-Ang University Hospital, Chung-Ang University College of Medicine, Seoul, Korea. Hauptthemen laut MEDLINE: Dendritic Cells, Prostatic Neoplasms, B7-H1 Antigen. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NRF, National Research Foundation of Korea.
Abstract (Originalsprache)
PURPOSE: We developed immune checkpoint molecules to target recombinant dendritic cells (DCs) and verified their anti-tumor efficacy and immune response against prostate cancer. MATERIALS AND METHODS: DCs were generated from mononuclear cells in the tibia and femur bone marrow of mice. We knocked down the programmed death ligand 1 (PD-L1) on monocyte-derived DCs through siRNA PD-L1. Cell surface antigens were immune fluorescently stained through flow cytometry to analyze cultured cell phenotypes. Furthermore, we evaluated the efficacy of monocyte-derived DCs and recombinant DCs in a prostate cancer mouse model with subcutaneous TRAMP-C1 cells. Lastly, DC-induced mixed lymphocyte and lymphocyte-only proliferations were compared to determine cultured DCs' function. RESULTS: Compared to the control group, siRNA PD-L1 therapeutic DC-treated mice exhibited significantly inhibited tumor volume and increased tumor cell apoptosis. Remarkably, this treatment substantially augmented interferon-gamma and interleukin-2 production by stimulating T-cells in an allogeneic mixed lymphocyte reaction. Moreover, we demonstrated that PD-L1 gene silencing improved cell proliferation and cytokine production. CONCLUSIONS: We developed monocyte-derived DCs transfected with PD-L1 siRNA from mouse bone marrow. Our study highlights that PD-L1 inhibition in DCs increases antigen-specific immune responses, corroborating previous immunotherapy methodology findings regarding castration-resistant prostate cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Chung-Ang University Hospital, Chung-Ang University College of Medicine, Seoul, Korea.
- Asan Institute for Life Sciences, Asan Medical Center, Seoul, Korea.
- Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
- Department of Urology, Ewha Womans University Mokdong Hospital, Ewha Womans University School of Medicine, Seoul, Korea. cskim37345806@gmail.com.
ORCID-Profile: Se Young Choi, Yunlim Kim, Bumjin Lim, Chung Beum Wee, In Ho Chang, Choung-Soo Kim
Förderung
- NRF
- National Research Foundation of Korea
Zitieren
APA
Choi, S. Y., Kim, Y., Lim, B., Wee, C. B., Chang, I. H., & Kim, C. S. (2024). Prostate cancer therapy using immune checkpoint molecules to target recombinant dendritic cells. Investigative and Clinical Urology. https://doi.org/10.4111/icu.20230348
Vancouver
Choi SY, Kim Y, Lim B, Wee CB, Chang IH, Kim CS. Prostate cancer therapy using immune checkpoint molecules to target recombinant dendritic cells. Investigative and Clinical Urology. 2024. doi:10.4111/icu.20230348
BibTeX
@article{Choi2024,
author = {Choi, Se Young and Kim, Yunlim and Lim, Bumjin and Wee, Chung Beum and Chang, In Ho and Kim, Choung-Soo},
title = {Prostate cancer therapy using immune checkpoint molecules to target recombinant dendritic cells},
journal = {Investigative and Clinical Urology},
year = {2024},
doi = {10.4111/icu.20230348}
}
EUVIMED